Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
Date:9/9/2009

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.

For a non-confidential information pack on BVA-201 contact Biovista at info@biovista.com.

About Biovista's BVA-201 trial in the MS EAE-MOG model

MS is a chronic inflammatory neurological disease. It is the most frequent non-traumatic disabling neurologic disease among young adults, with over 2.5 million patients worldwide. In the animal proof-of-concept trial, BVA-201 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-201 induced a statistically significant reduction of EAE severity, the magnitude of which was directly comparable to that caused by dexamethasone. Furthermore, BVA-201 protected neural axons and
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
3. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
4. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
5. Medivation Announces Participation in Upcoming Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale
10. American Oriental Bioengineering Announces September Investor Conferences Participation
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and FRANKLIN, Tenn. , July ... premier provider of health care services and one ... U.S., today announced that its parent company and ... definitive agreement with Medical Properties Trust, Inc. ("MPT") ... Capella for $900 million in cash.  The transaction is expected ...
(Date:7/27/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader ... Ways to GHS Labels . This video provides useful information on how to ... effectively labeling chemical containers. , “With the fourth and final deadline for HazCom/GHS ...
(Date:7/27/2015)... WORTH, Texas , July 27, 2015 ... Media Market by Type (Home-brew Media, Pre-formulated Media), by Application ... America , Europe , ... Forecast to 2019", The global biopreservation media market was valued ... to around $571.5 million by 2019, at a CAGR of ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Visual ... identify and celebrate the top 100 most innovative technologies and services of the past ... was named in the Software/Services category. The winners will be announced at the 2015 ...
Breaking Biology Technology:Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Brady Releases “3 Roads to GHS Labels” Video 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2
... only one-tenth the size of a human hair, but ... the intense heat and radiation of next generation nuclear ... power-generating reactors are being designed to provide low-cost electricity, ... not have. , The Department of Energy (DoE) ...
... Research &,Instrumentation, Inc. (CRi) announces the launch of ... brightfield or,fluorescent microscope into a multispectral imaging workstation. ... as embryos,zebrafish, plants, tissue culture and microtiter plates, ... macroscope. The Nuance 2 system will be,showcased at ...
... Inc. (OTC,Bulletin Board: SCIE) announced today that Jim Dorst ... and Chief Financial Officer., Jim Hitchin the Company,s ... of,experience in public medical device, manufacturing and software firms. ... ago. With a graduate,degree in accounting, he is well ...
Cached Biology Technology:Clemson researcher studies carbon fibers for nuclear reactor safety 2CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy 2Jim Dorst Joins SpectraScience as CFO 2
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... Thanks to a single-molecule imaging technique developed by ... mechanisms of an important DNA-regulating enzyme. Helicase enzymes ... have many other functions for DNA repair and maintenance. ... called PcrA involved in preventing unwanted recombination. A ...
... lipids and carbohydrates during exercise. The carbohydrates consist of ... glucose extracted from the blood. Being a major sink ... tissue for studying the intracellular signaling pathways leading to ... it is known that the contraction-induced signaling to stimulate ...
... University School of Medicine (BUSM) report that physicians who use ... on patients with an abnormal Pap test could increase the ... achieve resolution in less time than using traditional methods. These ... . Screening for cervical cancer with a Pap ...
Cached Biology News:Researchers advance understanding of enzyme that regulates DNA 2New molecular signaling cascade increases glucose uptake 2Electronic tracking system can improve follow-up after an abnormal Pap test 2
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Biology Products: